NCT06568328 Chimeric Natural Killer Receptor-Universal T Cells for Refractory GVHD
| NCT ID | NCT06568328 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Fujian Medical University |
| Condition | Graft vs Host Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 17 participants |
| Start Date | 2024-09-01 |
| Primary Completion | 2026-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 17 participants in total. It began in 2024-09-01 with a primary completion date of 2026-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a single arm, open-label, multi-center, pilot studies (Investigator Initiated Trial, IIT) to evaluate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of universal T-cells engineered with chimeric natural killer receptor (CNK-UT) to treat the patients with steroid-refractory/resistant or steroid-dependent GVHD.
Eligibility Criteria
Inclusion Criteria: 1. Aged 1\~70 years, male or female; 2. Participants diagnosed with grade II\~IV steroid-refractory/resistant or steroid-dependent GVHD after allogeneic hematopoietic stem cell transplantation who have failed treatment with ruxolitinib or at least one other second-line medication, or who are intolerant to these medications. 3. ECOG physical status score 0\~3; 4. Estimated life expectancy \> 12 weeks; 5. Female participants of childbearing age must undergo a serum or urine pregnancy test before enrollment, and the results must be negative, and agree to take acceptable measures to minimize the possibility of pregnancy during the trial; For female participants of childbearing age or male participants whose sexual partners are women of childbearing age, effective contraceptive measures should be taken during the study and for at least 6 months following the last dose of the study cells infusion. 6. Participants voluntarily participate in clinical trial; Understand and know this study, sign an informed consent form, and be willing to follow all experimental procedures. Exclusion Criteria: 1. Suffering from malignant tumors or diagnosed within 5 years before enrollment, excluding radical skin basal cell carcinoma, skin squamous cell carcinoma, thyroid cancer, breast cancer (ductal carcinoma in situ) and / or radical resection of carcinoma in situ. 2. Participants with a history of organ transplantation; 3. Participants who have previously undergone more than one allogeneic hematopoietic stem cell transplantation. 4. Uncontrolled hypertension as determined by principal investigator, a history of hypertensive crisis or hypertensive encephalopathy; symptomatic congestive heart failure (New York Heart Association classification III-IV); symptomatic or poorly controlled arrhythmias; a history of congenital long QT syndrome or a corrected QT interval (QTc) \> 500 ms at screening (calculated using the Fridericia method).. 5. Systemic diseases deemed unstable by principal investigator include, but are not limited to, severe pulmonary, hepatic, renal, or metabolic disorders that require pharmacological intervention (excluding complications related to allogeneic hematopoietic stem cell transplantation). 6. Active pulmonary tuberculosis (TB), who is receiving anti-tuberculosis treatment or has received anti-tuberculosis treatment within 1 year before enrollment; human immunodeficiency virus (HIV) infection, known syphilis infection. 7. Severe infections that are active or poorly controlled clinically. 8. Participants who have received treatment from other clinical trials within 12 weeks prior to the initiation of the study. 9. Participants who have previously used any gene therapy products prior to the initiation of the study. 10. Allergic to components of CNK-UT injection. 11. Participants suffer from known mental or substance abuse disorders, which may interfere with their ability to comply with research requirements. 12. Women who are pregnant or breastfeeding, as well as male or female participants who have planned for birth within 1 year after receiving medication. 13. Uncontrolled/uncorrectable metabolic disorders or other non-malignant organ diseases or systemic diseases or secondary reactions to cancer, which can lead to higher medical risk and/or uncertainty in survival assessments. 14. Other situations that the participant is identified by the investigator as unsuitable to participate in the study.
Contact & Investigator
Ting YANG, Prof.
PRINCIPAL INVESTIGATOR
First Affiliated Hospital of Fujian Medical University
Frequently Asked Questions
Who can join the NCT06568328 clinical trial?
This trial is open to participants of all sexes, aged 1 Year or older, up to 70 Years, studying Graft vs Host Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06568328 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06568328 currently recruiting?
Yes, NCT06568328 is actively recruiting participants. Contact the research team at yang.hopeting@gmail.com for enrollment information.
Where is the NCT06568328 trial being conducted?
This trial is being conducted at Fuzhou, China.
Who is sponsoring the NCT06568328 clinical trial?
NCT06568328 is sponsored by Fujian Medical University. The principal investigator is Ting YANG, Prof. at First Affiliated Hospital of Fujian Medical University. The trial plans to enroll 17 participants.